Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-03-20 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - VIRAL DISEASE BUSINESS UPDATE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. providing an update on its viral disease business, specifically mentioning sales figures for ritonavir tablets and clinical trial progress for ASC22. It is not a full financial report, audit, or earnings release. The document is relatively short (2407 characters) and serves to inform shareholders and potential investors about business developments rather than presenting comprehensive financial data or formal regulatory filings. There is no indication of voting results, management changes, or capital structure updates. The nature of the content aligns with a general business update announcement, which fits best under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories.
2023-03-20 English
ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
Annual Report Classification · 95% confidence The document is an announcement titled 'ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022' from Ascletis Pharma Inc. It contains detailed financial highlights, including revenue, gross profit/loss, loss before tax, and loss attributable to owners for the year ended December 31, 2022, with comparative figures for 2021. The document also includes a corporate profile, business overview, pipeline details, and a management discussion and analysis section. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes audited condensed consolidated annual results and detailed financial and operational data, which aligns with the characteristics of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement of a report or a certification letter. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-03-20 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS STATES NO BANK ACCOUNT IN SILICON VALLEY BANK OR ITS AFFILIATES
Regulatory Filings Classification · 95% confidence The document is a short announcement from Ascletis Pharma Inc. stating that the company has no bank account or deposits with Silicon Valley Bank or its affiliates. It is labeled as a "Voluntary Announcement" and does not contain any financial data, report, or detailed analysis. The length is only 1379 characters, which is quite short and does not constitute a full report. There is no indication of financial results, management changes, voting results, or other specific report content. This fits the profile of a Regulatory Filing (RNS) as a general announcement that does not fit into other specific categories.
2023-03-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
Share Issue/Capital Change Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, share options, and other related share capital information for Ascletis Pharma Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules. The content focuses on share capital movements and confirmations, typical of regulatory compliance filings related to share capital changes. It does not contain financial statements, earnings data, or management discussion. The document is about share capital movements and share options but does not announce new share issues or repurchases directly; it reports on movements and confirmations. Given the detailed share capital movement data and the nature of the report, it fits best under the category of Share Issue/Capital Change (SHA). The document length is about 5800 characters, which is sufficient for a substantive report rather than a brief announcement. Therefore, the classification is SHA with high confidence.
2023-03-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 28 February 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return concerning movements in securities, specifically focusing on authorized and issued share capital, share options, and confirmations related to securities issued by the company. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is regulatory in nature, reporting share capital and share option movements for the month ended 28 February 2023. It does not contain financial statements, management discussion, or earnings data, nor is it an announcement of a report publication. It is a regulatory filing reporting share capital movements and confirmations, which fits best under the category of Regulatory Filings (RNS).
2023-03-01 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS PRESENTED POSITIVE PHASE I CLINICAL DATA FOR BROAD-SPECTRUM ANTIVIRAL DOUBLE PRODRUG ASC10 AT CROI 2023
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding positive Phase I clinical trial data for their antiviral drug ASC10 presented at a scientific conference (CROI 2023). It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed investor presentation. The document is relatively short (4134 characters) and serves to inform shareholders and investors about recent business developments, specifically clinical trial progress. It is not a report itself but an announcement of clinical data presentation. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-02-21 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.